Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options
Largest study to date confirms non-steroidal anti-inflammatory medications do not result in worse COVID-19 outcomes
8 May 2021Most comprehensive studies to date find ‘insufficient evidence’ to support herbal, dietary supplements for weight loss
9 May 2021Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
